Last reviewed 2026-04-20 · How we verify

Adalimumab, solution for injection

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nasopharyngitis
• Alanine aminotransferase increased
• Bronchitis
• Headache
• Rheumatoid Arthritis
• Upper respiratory tract infection
• Hypertension
• Aspartate aminotransferase increased
• Gastrointestinal related
• Hypercholesterolaemia
• Urinary tract infection
• Dyslipidaemia

Key clinical trials

• Preventing Structural Damage in Early Psoriatic Arthritis (PHASE4)
• Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI (PHASE1, PHASE2)
• Adalimumab in JIA-associated Uveitis Stopping Trial (PHASE4)
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (PHASE3)
• Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH) (PHASE3)
• A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis (PHASE3)
• Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) (PHASE3)
• A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Adalimumab, solution for injection CI brief — competitive landscape report
• Adalimumab, solution for injection updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI